Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis

• Published in: Cancers Vol. 12; no. 8; p. 2042
• Main Authors: Azad, Taha, Rezaei, Reza, Surendran, Abera, Singaravelu, Ragunath, Boulton, Stephen, Dave, Jaahnavi, Bell, John C., Ilkow, Carolina S.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2020; MDPI
• Subjects: 1-Phosphatidylinositol 3-kinase; Apoptosis; Cancer; Carcinogenesis; Cell adhesion & migration; Cell growth; Cell proliferation; Gene expression; Health aspects; Hippo signaling; Kinases; Mammals; MAP kinase; Mutation; Observations; Phosphotransferases; Physiology; Proteins; receptor tyrosine kinases (RTKs); Review; Signal transduction; Stem cells; TAZ; Tumorigenesis; Tyrosine; YAP; Canada
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12082042

The Hippo pathway plays a critical role in tissue and organ growth under normal physiological conditions, and its dysregulation in malignant growth has made it an attractive target for therapeutic intervention in the fight against cancer. To date, its complex signaling mechanisms have made it difficult to identify strong therapeutic candidates. Hippo signaling is largely carried out by two main activated signaling pathways involving receptor tyrosine kinases (RTKs)—the RTK/RAS/PI3K and the RTK-RAS-MAPK pathways. However, several RTKs have also been shown to regulate this pathway to engage downstream Hippo effectors and ultimately influence cell proliferation. In this text, we attempt to review the diverse RTK signaling pathways that influence Hippo signaling in the context of oncogenesis.